Greenphire Expands Agreement with Merck to Help Reduce Financial and Travel Barriers for Clinical Trial Participants Worldwide
KING OF PRUSSIA, Pa., March 13, 2023 . Greenphire, the global leader in financial lifecycle management for clinical trials, today announced an expansion of its agreement with Merck, known as MSD outside the United States and Canada. This expanded... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 13, 2023 Category: Pharmaceuticals Source Type: clinical trials
Gene therapy candidate for amyotrophic lateral sclerosis (ALS) demonstrates bioactivities in a murine model of the disease
NEW YORK, March 13, 2023. ANEW MEDICAL, INC. ( " ANEW ' ' or the " Company " ), a medical product development company, announced results presented at the European Society of Cell and Gene Therapy (ESCGT) from preclinical in vivo studies of its lead... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 13, 2023 Category: Pharmaceuticals Source Type: clinical trials
Results from Astellas' Pivotal Phase 3 SKYLIGHT 1 ™ Study of Fezolinetant for Vasomotor Symptoms Due to Menopause Published in The Lancet
TOKYO, March 13, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., " Astellas " ) today announced The Lancet published detailed results from the pivotal Phase 3 SKYLIGHT 1™ study of fezolinetant, an... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 13, 2023 Category: Pharmaceuticals Source Type: clinical trials
Scientists Reveal a Potential New Approach to Treating Liver Cancer
March 13, 2023 -- Scientists at the National Institutes of Health and Massachusetts General Hospital in Boston have uncovered a potential new approach against liver cancer that could lead to the development of a new class of anticancer drugs. In a... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 13, 2023 Category: Pharmaceuticals Source Type: clinical trials
Patiromer for Treatment of Hyperkalaemia in Children From Birth to < 6 Years of Age
Condition: Hyperkalemia Intervention: Drug: Patiromer Sponsor: Vifor Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 13, 2023 Category: Research Source Type: clinical trials
